Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 35, 2020 - Issue 1
Submit an article Journal homepage
2,906
Views
17
CrossRef citations to date
0
Altmetric
Research Paper

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease

Serena Vittorioa Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina Viale Palatucci, Messina, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6092-5011View further author information
ORCID Icon,
Ilenia Adornatoa Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina Viale Palatucci, Messina, ItalyView further author information
,
Rosaria Gittoa Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina Viale Palatucci, Messina, ItalyORCID Iconhttps://orcid.org/0000-0003-0002-2253View further author information
ORCID Icon,
Samuel Peña-Díazb Institut de Biotecnologia i Biomedicina, Universitat Autonoma de Barcelona, Spain;c Departament de Bioquimica i Biologia Molecular, Universitat Autonoma de Barcelona, SpainView further author information
,
Salvador Venturab Institut de Biotecnologia i Biomedicina, Universitat Autonoma de Barcelona, Spain;c Departament de Bioquimica i Biologia Molecular, Universitat Autonoma de Barcelona, Spain;d ICREA, Passeig Lluis Companys 23, Barcelona, SpainView further author information
&
Laura De Lucaa Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina Viale Palatucci, Messina, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0614-5713View further author information
ORCID Icon
Pages 1727-1735 | Received 07 Jul 2020, Accepted 21 Aug 2020, Published online: 14 Sep 2020

References

  • Chakraborty A, Brauer S, Diwan A. Possible therapies of Parkinson’s disease: a review. J Clin Neurosci 2020;75:1–4.
  • Stoker TB, Torsney KM, Barker RA. Emerging treatment approaches for Parkinson’s disease. Front Neurosci 2018;12:693.
  • Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015;386:896–912.
  • Dickson DW. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012;2:a009258.
  • Save SS, Rachineni K, Hosur RV, Choudhary S. Natural compound safranal driven inhibition and dis-aggregation of α-synuclein fibrils. Int J Biol Macromol 2019;141:585–95.
  • Savitt D, Jankovic J. Targeting α-synuclein in Parkinson’s disease: progress towards the development of disease-modifying therapeutics. Drugs 2019;79:797–810.
  • Afitska K, Priss A, Yushchenko DA, Shvadchak VV. Structural optimization of inhibitors of α-synuclein fibril growth: affinity to the fibril end as a crucial factor. J Mol Biol 2020;432:967–77.
  • Kyriukha YA, Afitska K, Kurochka AS, et al. α-Synuclein dimers as potent inhibitors of fibrillization. J Med Chem 2019;62:10342–51.
  • Serpell LC, Berriman J, Jakes R, et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 2000;97:4897–902.
  • Ma L, Yang C, Zheng J, et al. Non-polyphenolic natural inhibitors of amyloid aggregation. Eur J Med Chem 2020;192:112197
  • Sangwan S, Sahay S, Murray KA, et al. Inhibition of synucleinopathic seeding by rationally designed inhibitors. Elife 2020;9:e46775.
  • Haddad F, Sawalha M, Khawaja Y, et al. Dopamine and levodopa prodrugs for the treatment of Parkinson's disease. Molecules 2017;23: 40.
  • Carrera I, Cacabelos R. Current drugs and potential future neuroprotective compounds for Parkinson's disease. Curr Neuropharmacol 2019;17:295–306.
  • Borovac JA. Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. Yale J Biol Med 2016;89:37–47.
  • O'Hara DM, Kalia SK, Kalia LV. Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease. Br J Pharmacol 2018;175:3080–9.
  • Peña-Díaz S, Pujols J, Conde-Giménez M, et al. ZPD-2, a small compound that inhibits α-synuclein amyloid aggregation and its seeded polymerization. Front Mol Neurosci 2019;12: 306.
  • Singh SK, Dutta A, Modi G. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease. Future Med Chem 2017;9:1039–53.
  • Shihabuddin LS, Brundin P, Greenamyre JT, et al. New frontiers in Parkinson’s disease: from genetics to the clinic. J Neurosci 2018;38:9375–82.
  • Teil M, Arotcarena ML, Faggiani E, et al. Targeting α-synuclein for PD therapeutics: a pursuit on all fronts. Biomolecules 2020;10:391.
  • Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005;45:160–9.
  • Oliveri V. Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation. Eur J Med Chem 2019;167:10–36.
  • Kolodina AA, Gaponenko NI, Lesin AV. Synthesis and opening of the thiadiazine ring in 6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines. Russ Chem B. 2008;57:1273–6.
  • Pujols J, Peña-Díaz S, Conde-Giménez M, et al. High-throughput screening methodology to identify alpha-synuclein aggregation inhibitors. Int J Mol Sci 2017;18: 478.
  • Pujols J, Peña-Díaz S, Lázaro DF, et al. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci USA 2018;115:10481–6.
  • Crespo R, Villar-Alvarez E, Taboada P, et al. What can the kinetics of amyloid fibril formation tell about off-pathway aggregation? J Biol Chem 2016;291:2018–32.
  • Pedretti A, Villa L, Vistoli G. VEGA - an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. J Comput Aid Mol Des 2004;18:167–73.
  • Dassault Systèmes BIOVIA. BIOVIA Discovery Studio Visualizer, v20. San Diego: Dassault Systèmes; 2020.
  • Gitto R, De Luca L, Ferro S, et al. Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors. Bioorg Med Chem 2014;22:1040–8.
  • Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
  • Tuttle MD, Comellas G, Nieuwkoop AJ, et al. Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol 2016;23:409–15.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.